secwatch.observer — SEC 8-K summary
======================================

Issuer:     CervoMed Inc. (CRVO)
CIK:        0001053691
Form:       8-K
Filed at:   2023-03-30T23:59:59+00:00
Accession:  0001437749-23-008519
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.90
Item codes: 1.01, 5.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Diffusion Pharmaceuticals to merge with EIP Pharma; EIP shareholders to own ~77% of combined company
--------------------------------------------------------------------------------

- EIP stockholders will own ~77.3% and Diffusion stockholders ~22.7% of combined company on a fully-diluted basis.
- Combined company to be renamed CervoMed Inc.; board will have 5 EIP-designated and 2 Diffusion-designated directors.
- John Alam (EIP CEO) to become CEO; Robert Cobuzzi (Diffusion CEO) to become COO; William Tanner (EIP CFO) to become CFO.
- Lock-up agreements: most EIP holders subject to 180-day lockup; John Alam, Sylvie Grégoire, and two trusts subject to 12-month lockup.
- Merger expected to close by August 31, 2023; termination fee of $765,000 payable by Diffusion under certain conditions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1053691/000143774923008519/0001437749-23-008519-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1053691/000143774923008519/dffn20230329_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-008519

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer